Crescent Biopharma Announces Grants of Inducement Awards

Rhea-AI Summary

Crescent Biopharma (Nasdaq: CBIO) granted stock options as equity inducement awards to five non-executive employees under its 2025 Employment Inducement Incentive Award Plan.

The awards cover 129,075 shares with a 10-year term and a per-share exercise price of $18.52, vesting over four years, subject to continued service.

Argus May 13 session

+6.23% close to close 0.8x rel. volume Open Argus

Details

News Market Reaction – CBIO

On May 13, the first trading day after this news, CBIO closed 6.23% above the previous close.

Data tracked by StockTitan Argus for the May 13 session.

Key Figures

Option shares granted: 129,075 shares Exercise price: $18.52 Option term: 10 years +5 more

Option shares granted

129,075 shares

Aggregate options granted to five non-executive employees

Exercise price

$18.52

Exercise price equals Nasdaq closing price on May 11, 2026

Option term

10 years

Term of inducement stock options under the Inducement Plan

Initial vesting

1/4 of shares

Vests on first anniversary of each employee’s start date

Ongoing vesting

1/48 of shares

Vests monthly after first anniversary, subject to continuous service

Current share price

$18.46

Price before news; 24h move -1.28%

52-week high

$27.41

Pre-news 52-week high level

52-week low

$18.46

Pre-news 52-week low; equal to current price

Historical Context

5 past events · Latest: 2026-05-06

5 events

1. 2026-05-06

   Investor conferences

   24h Move

   -0.1%

   Management scheduled presentations at three May 2026 healthcare investor conferences.

2. 2026-04-29

   Q1 2026 earnings

   24h Move

   +6.8%

   Reported Q1 2026 results with $189.2M cash and funding outlook into 2028.

3. 2026-04-24

   Inducement awards

   24h Move

   +1.4%

   Granted options for 12,525 shares to two non-executive employees under inducement plan.

4. 2026-03-27

   Inducement awards

   24h Move

   +9.6%

   Approved options for 35,325 shares to three non-executive employees with 10-year term.

5. 2026-03-06

   Inducement awards

   24h Move

   -0.4%

   Inducement option awards totaling 45,675 shares to two non-executive employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

equity inducement awards, Nasdaq Listing Rule 5635(c)(4), exercise price

3 terms

equity inducement awards financial

"approved the grant of options to purchase an aggregate of 129,075 shares... as equity inducement awards"

Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.

Nasdaq Listing Rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4). The options were granted with a 10-year term"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"a 10-year term and an exercise price equal to $18.52, the closing price per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 129,075 shares of the Company’s ordinary shares to five non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on May 11, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).

The options were granted with a 10-year term and an exercise price equal to $18.52, the closing price per share of Crescent’s ordinary shares as reported by Nasdaq on May 11, 2026. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.

About Crescent Biopharma

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.

Contacts

Investors
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586

Media
Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement stock option awards did Crescent Biopharma (CBIO) grant on May 11, 2026?

Crescent Biopharma granted options to purchase an aggregate 129,075 ordinary shares as equity inducement awards. According to Crescent Biopharma, these options were granted to five non-executive employees under the 2025 Employment Inducement Incentive Award Plan, as amended.

What is the exercise price and term of the new Crescent Biopharma (CBIO) inducement options?

The inducement options have a 10-year term and an exercise price of $18.52 per share. According to Crescent Biopharma, this price equals the closing price of its ordinary shares on Nasdaq on May 11, 2026.

How do Crescent Biopharma (CBIO) inducement option awards vest for new employees?

The options vest 25% on the first anniversary of each employee’s start date, then monthly thereafter. According to Crescent Biopharma, one-forty-eighth of the shares vest monthly over the remaining three years, subject to continuous service.

Why did Crescent Biopharma (CBIO) issue inducement awards under Nasdaq Listing Rule 5635(c)(4)?

Crescent Biopharma issued the options as equity inducement awards material to each employee’s acceptance of employment. According to Crescent Biopharma, the grants were approved by the Board’s Compensation Committee in line with Nasdaq Listing Rule 5635(c)(4).

Who received the Crescent Biopharma (CBIO) inducement stock options announced in May 2026?

Five non-executive employees received the inducement option grants from Crescent Biopharma. According to Crescent Biopharma, the awards were made under the 2025 Employment Inducement Incentive Award Plan to support recruitment and retention of these new hires.